AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (New) A therapeutic composition consisting essentially of a reduced isoalpha acid (RIAA) selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, and dihydro-isoadhumulone and an isoalpha acid (IAA) selected from the group consisting of isohumulone, isocohumulone, and isoadhumulone, wherein the combination of said RIAA and IAA in said composition has a combination index (CI) of less than 1 for synergistic inhibition of PGE2 production.

15. (New) The composition of claim 1, wherein said composition is capable of reducing PGE_2 mediated inflammation.

16. (New) The composition of claim 1, wherein the RIAA and IAA comprise two compounds of Genus A having the formula:

(Genus A), 

,

wherein R' is selected from the group consisting of carbonyl, hydroxyl;

and wherein R" is selected from the group consisting of $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, and $CH(CH_3)CH_2CH_3$.

17. (New) The composition for use according to claim 1, wherein the RIAA and IAA are derived from hops.

18. (New) The composition for use according to claim 1, wherein the composition comprises from about 0.5 mg to about 500 mg of the RIAA.

19. (New) The composition for use according to claim 1, wherein the composition comprises from about 0.5 mg to about 500 mg of the IAA.

20. (New) The composition for use according to claim 1, wherein the composition comprises from about 50 mg to about 7500 mg of the RIAA.

21. (New) The composition for use according to claim 1, wherein the composition comprises from about 50 mg to about 7500 mg of the IAA.

22. (New) The composition for use according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

23. (New) The composition for use according to claim 1, wherein the composition is administered orally, topically, parenterally, or rectally.

24. (New) A method for reducing PGE2 mediated inflammation, comprising administering a composition consisting essentially of a reduced isoalpha acid (RIAA) selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, and dihydro-isoadhumulone and an isoalpha acid (IAA) selected from the group consisting of isohumulone, isocohumulone, and isoadhumulone, wherein the RIAA and IAA are in synergistic amounts or ratios with a combination index (CI) of less than 1 for inhibition of PGE2 production

25. (New) The method of claim 13, wherein the composition comprises from about 0.5 mg to about 500 mg of the RIAA.

26. (New) The method of claim 13, wherein the composition comprises from about 0.5 mg to about 500 mg of the IAA.

27. (New) The method of claim 13, wherein the composition comprises from about 50 mg to about 7500 mg of the RIAA.

28. (New) The method of claim 13, wherein the composition comprises from about 50 mg to about 7500 mg of the IAA19.

29. (New) The method of claim 13, wherein the composition further comprises a pharmaceutically acceptable carrier.

30. (New) The method of claim 13, wherein the composition is administered orally, topically, parenterally, or rectally.